Impacto de la protocolización de mezclas intravenosas de fármacos vasoactivos en el coste del tratamiento del paciente crítico

Cuesta-López , Isabel; Sánchez-Cuervo, Marina; Candela-Toha, Ángel; Benedí-González, Juana; Bermejo-Vicedo, Teresa.
Farm. hosp ; 42(2): 62-67, mar.-abr. 2018. tab
Artículo en Español | IBECS (España) | ID: ibc-171663

Documentos relacionados

  1. Impact of the implementation of vasoactive drug protocols on costs in the treatment of critically ill patients.
  2. Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia.
  3. Cost-Utility of Sildenafil for Persistent Pulmonary Hypertension of the Newborn.
  4. Nicardipine Versus Nitroprusside-The Budget-Friendly Battle for Baby Blood Pressure Control.
  5. Fund Black scientists.
  6. Nicardipine or Nitroprusside for Postoperative Blood Pressure Control in Infants After Surgery for Congenital Heart Disease: Single-Center Retrospective Noninferiority and Cost Analysis, 2016-2020.
  7. Electrolyte Analysis and Replacement: Challenging a Paradigm in Surgical Patients.
  8. From scientific discovery to cures: bright stars within a galaxy.
  9. The economics of a pediatric surgical ICU.
  10. Addressing Serious Illness Care in Medicare Advantage.